RU97112474A - MEDICINAL EMISSION SURGICAL IMPLANT OR BANDBANDING MATERIAL - Google Patents

MEDICINAL EMISSION SURGICAL IMPLANT OR BANDBANDING MATERIAL

Info

Publication number
RU97112474A
RU97112474A RU97112474/14A RU97112474A RU97112474A RU 97112474 A RU97112474 A RU 97112474A RU 97112474/14 A RU97112474/14 A RU 97112474/14A RU 97112474 A RU97112474 A RU 97112474A RU 97112474 A RU97112474 A RU 97112474A
Authority
RU
Russia
Prior art keywords
dressing
implant
drug
suture
releasing
Prior art date
Application number
RU97112474/14A
Other languages
Russian (ru)
Other versions
RU2176525C2 (en
Inventor
Х.Хейнес Дункан
Х.Бедекер Бен
Д.Клайн Марк
Original Assignee
Дзе Гавермент оф Дзе Юнайтед Стэйтс, Эз Репрезентед Бай Дзе Секретари оф Дзе Арми
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/345,889 external-priority patent/US5660854A/en
Application filed by Дзе Гавермент оф Дзе Юнайтед Стэйтс, Эз Репрезентед Бай Дзе Секретари оф Дзе Арми filed Critical Дзе Гавермент оф Дзе Юнайтед Стэйтс, Эз Репрезентед Бай Дзе Секретари оф Дзе Арми
Publication of RU97112474A publication Critical patent/RU97112474A/en
Application granted granted Critical
Publication of RU2176525C2 publication Critical patent/RU2176525C2/en

Links

Claims (54)

1. Хирургический имплантат, перевязочный материал или шовный материал, выполненный с возможностью применения к ткани человека или животного, содержащий:
волокнистый носитель,
твердые микрочастицы фармацевтического препарата размером от около 20 нанометров до около 30 микрон, несомые указанными волокнами, и
вспомогательное средство для сцепления указанных микрочастиц с указанными волокнами.1. A surgical implant, dressing or suture material, made with the possibility of application to human or animal tissue, containing:
fiber carrier
solid microparticles of a pharmaceutical preparation ranging in size from about 20 nanometers to about 30 microns carried by said fibers, and
auxiliary means for coupling said microparticles with said fibers. 2. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанные частицы фармацевтического препарата покрыты указанным вспомогательным средством, содержащим липидную оболочку. 2. A surgical implant, dressing or suture according to claim 1, wherein said particles of a pharmaceutical preparation are coated with said adjuvant containing a lipid membrane. 3. Хирургический имплантат, перевязочное средство или шовный материал по п. 2, в котором указанный липид является амфипатическим. 3. The surgical implant, dressing or suture according to claim 2, wherein said lipid is amphipathic. 4. Хирургический имплантат, перевязочное средство или шовный материал по п. 2, в котором указанный липид выбран из группы, состоящей из лецитина, фосфатидной кислоты, фосфатидилсерина, фосфатидилинозита, кардиолипина, фосфатидилглицерина, фосфатидилэтаноламина, сфингомиелина, моноглицеридов, алкиламинов с длинной цепью, жирных кислот, холестерина: триглицеридов при комнатной температуре, диглицеридов, твердых при комнатной температуре, восков и их сочетаний. 4. The surgical implant, dressing or suture material according to claim 2, wherein said lipid is selected from the group consisting of lecithin, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin, phosphatidylglycerol, phosphatidylethanolamine, sphingomyelin, long chain monoglycerides, alkyl monoglycerides, acids, cholesterol: triglycerides at room temperature, diglycerides, solid at room temperature, waxes and their combinations. 5. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанным носителем является абсорбируемый имплантат. 5. The surgical implant, dressing or suture according to claim 1, wherein said carrier is an absorbable implant. 6. Хирургический имплантат, перевязочный материал или шовный материал по п. 5, в котором указанный имплантат содержит стерильную желатиновую губку. 6. The surgical implant, dressing or suture according to claim 5, wherein said implant contains a sterile gelatin sponge. 7. Хирургический имплантат, перевязочный материал или шовный материал по п. 5, в котором указанный имплантат содержит целлюлозу. 7. The surgical implant, dressing or suture according to claim 5, wherein said implant contains cellulose. 8. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором носителем является местный перевязочный материал. 8. A surgical implant, dressing or suture according to claim 1, wherein the carrier is a local dressing. 9. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанным носителем является шовный материал. 9. A surgical implant, dressing or suture according to claim 1, wherein said carrier is suture. 10. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанный фармацевтический препарат является не растворимым в воде. 10. A surgical implant, dressing or suture according to claim 1, wherein said pharmaceutical preparation is insoluble in water. 11. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанный фармацевтический препарат выбран из группы, состоящей из антисептических средств, антибиотиков, противовоспалительных средств, местных анестезирующих средств, стимуляторов роста тканей, ингибиторов разрушения тканей и их сочетаний. 11. The surgical implant, dressing or suture material according to claim 1, wherein said pharmaceutical preparation is selected from the group consisting of antiseptics, antibiotics, anti-inflammatory drugs, local anesthetics, tissue growth stimulants, tissue destruction inhibitors, and combinations thereof. 12. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанными микрочастицами являются микрокристаллы. 12. A surgical implant, dressing or suture according to claim 1, wherein said microparticles are microcrystals. 13. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанные частицы фармацевтического препарата имеют диаметр менее 10 микрон. 13. A surgical implant, dressing or suture according to claim 1, wherein said particles of the pharmaceutical preparation have a diameter of less than 10 microns. 14. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанный волокнистый носитель выполнен с возможностью удерживания до 4 грамм фармацевтического препарата на один грамм носителя. 14. A surgical implant, dressing or suture material according to claim 1, wherein said fibrous carrier is configured to hold up to 4 grams of pharmaceutical preparation per gram of carrier. 15. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, содержащий, кроме того, консервант. 15. A surgical implant, dressing or suture according to claim 1, further comprising a preservative. 16. Хирургический имплантат, перевязочный материал или шовный материал по п. 15, в котором указанный консервант выбран из группы, состоящей из бензалконийхлорида, бензэтонийхлорида, пропилпарабена, бутилпарабена, хлорбутанола, бензилового спирта, фенола, бензоата натрия и этилендиаминтетрауксусной кислоты. 16. The surgical implant, dressing or suture according to claim 15, wherein said preservative is selected from the group consisting of benzalkonium chloride, benzethonium chloride, propyl paraben, butyl paraben, chlorobutanol, benzyl alcohol, phenol, sodium benzoate and ethylenediaminetetraacetic acid. 17. Способ изготовления выделяющего лекарственное средство перевязочного материала или имплантата, содержащий стадии:
обеспечивают волокнистый материал носителя,
обеспечивают суспензию лекарственного средства в твердом виде из микрочастиц или микрокристаллов в растворителе, причем указанные микрочастицы или микрокристаллы имеют размер от около 20 нанометров до около 30 микрон,
пропитывают указанный материал носителя в указанной суспензии, и
выпаривают указанный растворитель.17. A method of manufacturing a drug-releasing dressing or implant, comprising the steps of:
provide fibrous carrier material
provide a suspension of the drug in solid form from microparticles or microcrystals in a solvent, said microparticles or microcrystals having a size of from about 20 nanometers to about 30 microns,
impregnate the specified carrier material in the specified suspension, and
the specified solvent is evaporated. 18. Способ изготовления выделяющего лекарственное средство перевязочного материала или имплантата по п. 17, в котором указанная суспензия, кроме того, содержит вспомогательное средство для покрытия указанного лекарственного средства. 18. A method of manufacturing a drug-releasing dressing or implant according to claim 17, wherein said suspension further comprises an auxiliary agent for coating said drug. 19. Способ изготовления выделяющего лекарственное средство перевязочного материала или имплантата по п. 18, в котором в качестве указанного вспомогательного средства используют липид, выбранный из группы, состоящей из лецитина, фосфатидной кислоты, фосфатидилсерина, фосфатидилинозита, кардиолипина, фосфатидилглицерина, фосфатидилэтаноламина, сфингомиелина, моноглицеридов, алкиламинов с длинной цепью, жирных кислот, триглицеридов, диглицеридов, твердых при комнатной температуре, и восков. 19. A method of manufacturing a drug-releasing dressing or implant according to claim 18, wherein the indicated adjuvant is a lipid selected from the group consisting of lecithin, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin, phosphatidylglycerol, phosphatidylethanolamine, sphingomyelinidin, monfogelierilin, , long chain alkyl amines, fatty acids, triglycerides, diglycerides, solid at room temperature, and waxes. 20. Способ изготовления перевязочного материала или имплантата по п. 17, в котором указанные микрочастицы или микрокристаллы имеют размеры около 20 нанометров - 30 микрон. 20. A method of manufacturing a dressing material or implant according to claim 17, in which these microparticles or microcrystals have a size of about 20 nanometers - 30 microns. 21. Способ изготовления перевязочного материала или имплантата по п. 17, в котором указанные микрочастицы или микрокристаллы не растворимы в воде. 21. A method of manufacturing a dressing or implant according to claim 17, wherein said microparticles or microcrystals are not soluble in water. 22. Способ изготовления перевязочного материала или имплантата по п. 17, в котором указанный фармацевтический препарат выбирают из группы, состоящей из антисептических средств, антибиотиков, противовоспалительных средств, местных анестезирующих средств, стимуляторов роста тканей, инигибиторов разрушения тканей и их сочетаний. 22. A method of manufacturing a dressing or implant according to claim 17, wherein said pharmaceutical preparation is selected from the group consisting of antiseptic agents, antibiotics, anti-inflammatory drugs, local anesthetics, tissue growth stimulants, tissue destruction inhibitors, and combinations thereof. 23. Способ управляемой доставки лекарственного средства к ткани животного или человека, содержащий применение к указанной ткани хирургического имплантата, перевязочного материала или шовного материала по п. 1. 23. A method for the controlled delivery of a drug to tissue of an animal or human, comprising applying to said tissue a surgical implant, dressing or suture according to claim 1. 24. Способ применения лекарственного вещества к животному или человеку, содержащий стадии использования волокнистого перевязочного материала или хирургического имплантата, пропитанного твердыми частицами фармакологически активного, не растворимого в воде лекарственного вещества, при этом твердые частицы покрыты оболочкообразующим амфипатическим липидом. 24. A method of applying a drug substance to an animal or person, comprising the steps of using a fibrous dressing or surgical implant impregnated with solid particles of a pharmacologically active, water-insoluble drug substance, wherein the solid particles are coated with a shell-forming amphipathic lipid. 25. Способ по п. 24, при котором указанный липид выбирают из группы, состоящей из лецитина, фосфатидной кислоты, фосфатидилсерина, фосфатидилинозита, кардиолипина, фосфатидилглицерина, фосфатидилэтаноламина, сфингомиелина, моноглицеридов, алкиламинов с длинной цепью, жирных кислот, триглицеридов, диглицеридов, твердых при комнатной температуре, и восков. 25. The method of claim 24, wherein said lipid is selected from the group consisting of lecithin, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin, phosphatidylglycerol, phosphatidylethanolamine, sphingomyelin, monoglycerides, long chain alkyl amines, fatty acids, triglycerides at room temperature, and waxes. 26. Способ по п. 24, при котором указанные частицы имеют размеры около 20 нанометров - 30 микрон. 26. The method according to p. 24, wherein said particles have a size of about 20 nanometers - 30 microns. 27. Способ по п. 24, при котором указанные частицы не растворимы в воде. 27. The method according to p. 24, wherein said particles are not soluble in water. 28. Хирургический имплантат, перевязочный материал или шовный материал по п. 1, в котором указанные частицы фармацевтического препарата покрыты водорастворимым вспомогательным средством, выбранным из группы, состоящей из коллагена, желатина, карбоксиметилцеллюлозы, гидроксиэтилцеллюлозы, гидроксипропилцеллюлозы, гидроксипропилметилцеллюлозы, повидона, бензалконийхлорида и бензэтонийхлорида. 28. The surgical implant, dressing or suture material according to claim 1, wherein said particles of the pharmaceutical preparation are coated with a water-soluble adjuvant selected from the group consisting of collagen, gelatin, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone chloride and benzalkyl chloride. 29. Способ изготовления выделяющего лекарственное средство перевязочного материала или имплантата по п. 17, при котором указанная суспензия содержит, кроме того, водорастворимое вспомогательное средство, выбранное из группы, состоящей из коллагена, желатина, карбоксиметилцеллюлозы, гидроксиэтилцеллюлозы, гидроксипропилцеллюлозы, гидроксипропилметилцеллюлозы, повидона, бензалконийхлорида и бензэтонийхлорида. 29. A method of manufacturing a drug-releasing dressing or implant according to claim 17, wherein said suspension comprises, in addition, a water-soluble auxiliary selected from the group consisting of collagen, gelatin, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone and benzethonium chloride. 30. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал, содержащий:
носитель, состоящий, по существу, из волокон, имеющих диаметр от около 0,1 микрометра до около 100 микрометров и покрытых многослойной, амфифатической оболочкой, и
фармацевтический препарат, связанный с указанными волокнами с возможностью выделения и содержащий твердые микрочастицы размером от около 20 нанометров до около 20 микрометров, покрытые многослойной, амфифатической оболочкой.30. A surgical-implant, dressing, or suture-releasing drug, comprising:
a carrier consisting essentially of fibers having a diameter of from about 0.1 micrometers to about 100 micrometers and coated with a multilayer, amphiphatic shell, and
a pharmaceutical preparation associated with these fibers with the possibility of isolation and containing solid microparticles ranging in size from about 20 nanometers to about 20 micrometers, coated with a multilayer, amphiphatic shell. 31. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 30, в котором указанным носителем является пористая основа с указанными волокнами, имеющими ковалентно образованные поперечные связи. 31. A surgical-releasing drug implant, dressing or suture according to claim 30, wherein said carrier is a porous base with said fibers having covalently formed cross-links. 32. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 30, в котором указанный носитель выполнен нитеобразным и содержит многочисленные пряди указанных волокон. 32. A surgical-releasing drug implant, dressing or suture according to claim 30, wherein said carrier is thread-like and contains numerous strands of said fibers. 33. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 30, в котором указанный фармацевтический препарат выбран из группы, состоящей из антисептических средств, антибиотиков, противовоспалительных средств, местных анестезирующих средств, стимуляторов роста тканей, ингибиторов разрушений тканей или их сочетаний. 33. A surgical-releasing drug implant, dressing or suture according to claim 30, wherein said pharmaceutical is selected from the group consisting of antiseptics, antibiotics, anti-inflammatory drugs, local anesthetics, tissue growth stimulators, tissue damage inhibitors or their combinations. 34. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 30, кроме того, содержит консервант. 34. The surgical-releasing drug implant, dressing, or suture material of claim 30 further comprises a preservative. 35. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 34, в котором указанный консервант выбран из группы, состоящей из бензалконийхлорида, бензэтонийхлорида, пропилпарабена, бутилпарабена, хлорбутанола, бензилового спирта, фенола, бензоата натрия и этилендиаминтетрауксусной кислоты. 35. The drug-releasing surgical implant, dressing, or suture material of claim 34, wherein said preservative is selected from the group consisting of benzalkonium chloride, benzethonium chloride, propyl paraben, butyl paraben, chlorobutanol, benzyl alcohol, phenol, sodium benzoate, and ethylene diamine acid. 36. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 30, в котором указанная многослойная, амфипатическая оболочка состоит из вещества, выбранного из группы, состоящей из лецитина, фосфатидной кислоты, фосфатидилсерина, фосфатидилинозита, кардиолипина, фосфатидилглицерина, фосфатидилэтаноламина, сфингомиелина и моноглицеридов. 36. A drug-releasing surgical implant, dressing or suture material according to claim 30, wherein said multilayer, amphipathic membrane consists of a substance selected from the group consisting of lecithin, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin, phosphatidylglycerol, phosphatide sphingomyelin and monoglycerides. 37. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал, содержащий:
носитель, состоящий, по существу, из волокон, имеющих диаметр от около 0,1 микрометра до около 100 микрометров, и
фармацевтический препарат, связанный с указанными волокнами с возможностью выделения и содержащий твердые микрочастицы размером от около 20 нанометров до около 20 микрометров,
при этом указанные волокна и указанные микрочастицы покрыты каждые веществом, выбранным из группы, состоящей из лецитина, фосфатидной кислоты, фосфатидилсерина, фосфатидилинозита, кардиолипина, фосфатидилглицерина, фосфатидилэтаноламина, сфингомиелина, моноглицеридов, алкиламинов с длинной цепью, жирных кислот, триглицеридов, диглицеридов и восков.37. Surgical implant, dressing, or suture material, drug-containing, containing:
a carrier consisting essentially of fibers having a diameter of from about 0.1 micrometers to about 100 micrometers, and
a pharmaceutical preparation associated with these fibers with the possibility of isolation and containing solid microparticles ranging in size from about 20 nanometers to about 20 micrometers,
wherein said fibers and said microparticles are coated with each substance selected from the group consisting of lecithin, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin, phosphatidylglycerol, phosphatidylethanolamine, sphingomyelin, monoglycerides, long chain alkyl amines, fatty acids, fatty acids. 38. Выделяющий лекарственное средство хирургический имплантат по п. 37, в котором указанным носителем является пористая основа с указанными волокнами, имеющими ковалентно образованные поперечные связи. 38. The surgical-releasing drug implant of claim 37, wherein said carrier is a porous base with said fibers having covalently formed transverse bonds. 39. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 37, в котором указанный фармацевтический препарат выбран из группы, состоящей из антисептических средств, антибиотиков, противовоспалительных средств, местных анестезирующих средств, стимуляторов роста тканей, ингибиторов разрушения тканей и их сочетаний. 39. The drug-releasing surgical implant, dressing, or suture material of claim 37, wherein said pharmaceutical preparation is selected from the group consisting of antiseptics, antibiotics, anti-inflammatory drugs, local anesthetics, tissue growth stimulators, tissue destruction inhibitors, and their combinations. 40. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 37, кроме того, содержит консервант. 40. The surgical-releasing drug implant, dressing, or suture material of claim 37 further comprises a preservative. 41. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 37, в котором указанным покрывающим веществом является лецитин. 41. A drug-releasing surgical implant, dressing or suture according to claim 37, wherein said coating agent is lecithin. 42. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 30, в котором указанным покрывающим веществом является лецитин. 42. A drug-releasing surgical implant, dressing or suture according to claim 30, wherein said coating agent is lecithin. 43. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал, содержащий:
носитель, содержащий фармацевтически приемлемую волокнистую основу,
фармацевтический препарат, содержащий микрочастицы размером от около 20 нанометров до около 20 микрометров, связанные с указанными волокнами с возможностью выделения,
при этом указанные волокна и указанные микрочастицы покрыты каждые вспомогательным средством, выбранным из группы, состоящей из коллагена, желатина, карбоксиметилцеллюлозы, гидроксипропилцеллюлозы, гидроксипропилметилцеллюлозы, повидона, бензалконийхлорида, бензэтонийхлорида, алкиламинов с длинной цепью, холестерина, жирных кислот и их солей, триглицеридов, диглицеридов и восков.43. A drug-releasing surgical implant, dressing or suture containing:
a carrier containing a pharmaceutically acceptable fibrous base,
a pharmaceutical preparation containing microparticles ranging in size from about 20 nanometers to about 20 micrometers, associated with these fibers with the possibility of isolation,
wherein said fibers and said microparticles are coated with each auxiliary agent selected from the group consisting of collagen, gelatin, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone, benzalkonium chloride, benzethonium chloride, long chain alkyl amines, cholesterol, fatty acids and their salts, and their salts and waxes. 44. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанная волокнистая основа содержит волокна, имеющие диаметр от около 0,1 до около 100 микрометров. 44. A drug-releasing surgical implant, dressing or suture according to claim 43, wherein said fibrous base contains fibers having a diameter of from about 0.1 to about 100 micrometers. 45. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанный фармацевтический препарат выбран из группы, состоящей из антисептических средств, антибиотиков, противовоспалительных средств, местных анестезирующих средств, стимуляторов роста тканей, ингибиторов разрушения тканей и их сочетаний. 45. The surgical-releasing drug implant, dressing, or suture material of claim 43, wherein said pharmaceutical preparation is selected from the group consisting of antiseptics, antibiotics, anti-inflammatory drugs, local anesthetics, tissue growth stimulators, tissue destruction inhibitors, and their combinations. 46. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п .43, кроме того, содержит консервант. 46. The surgical-releasing drug implant, dressing, or suture according to claim 43 further comprises a preservative. 47. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 46, в котором указанный консервант выбран из группы, состоящей из бензалконийхлорида, бензэтонийхлорида, пропилпарабена, бутилпарабена, хлорбутанола, бензилового спирта, фенола, бензоата натрия и этилендиаминтетрауксусной кислоты. 47. A drug-releasing surgical implant, dressing or suture according to claim 46, wherein said preservative is selected from the group consisting of benzalkonium chloride, benzethonium chloride, propyl paraben, butyl paraben, chlorobutanol, benzyl alcohol, phenol, sodium benzoate and ethylenediaminetetraux. 48. Хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанные микрочастицы фармацевтического препарата меньше 10 микрон. 48. A surgical implant, dressing or suture according to claim 43, wherein said microparticles of the pharmaceutical preparation are less than 10 microns. 49. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанный носитель выполнен с возможностью удерживания до около 4 грамм фармацевтического препарата на один грамм носителя. 49. A drug-releasing surgical implant, dressing or suture according to claim 43, wherein said carrier is capable of holding up to about 4 grams of pharmaceutical preparation per gram of carrier. 50. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанная соль жирной кислоты выбрана из группы, состоящей из стеарата кальция, стеарата магния, стеарата натрия и глицерилмоностеарата. 50. The drug-releasing surgical implant, dressing, or suture material of claim 43, wherein said fatty acid salt is selected from the group consisting of calcium stearate, magnesium stearate, sodium stearate, and glyceryl monostearate. 51. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанное вспомогательное средство, кроме того, включает в себя ионное поверхностно-активное вещество, содержащее лаурилсульфат натрия для способствования включению и выделению фармацевтического препарата. 51. The drug-releasing surgical implant, dressing or suture according to claim 43, wherein said adjuvant further comprises an ionic surfactant containing sodium lauryl sulfate to facilitate incorporation and excretion of the pharmaceutical preparation. 52. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанное вспомогательное средство, кроме того, включает в себя неионное поверхностно-активное вещество, выбранное из группы, состоящей из полиоксамеров, полиоксилстеаратов, полисорбатов, полипропиленгликоля и сложных эфиров сорбита и жирных кислот. 52. A drug-releasing surgical implant, dressing or suture according to claim 43, wherein said adjuvant further includes a non-ionic surfactant selected from the group consisting of polyoxamers, polyoxyl stearates, polysorbates, polypropylene glycol and esters of sorbitol and fatty acids. 53. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанная волокнистая основа выбрана из группы, состоящей из сшитого коллагена или желатина, целлюлозы и ее производных, пирролидона, акрилатов, полибутиратов, поливалератов, полигликолевой кислоты, полиглактина и поли-D,L-лактата. 53. The surgical-releasing drug implant, dressing, or suture material of claim 43, wherein said fibrous base is selected from the group consisting of cross-linked collagen or gelatin, cellulose and its derivatives, pyrrolidone, acrylates, polybutyrates, polyvalerates, polyglycolic acid, polyglactin and poly-D, L-lactate. 54. Выделяющий лекарственное средство хирургический имплантат, перевязочный материал или шовный материал по п. 43, в котором указанной волокнистой основой является абсорбируемая желатиновая губка. 54. A drug-releasing surgical implant, dressing or suture according to claim 43, wherein said fibrous base is an absorbable gelatin sponge.
RU97112474/14A 1994-11-28 1995-11-28 Surgical implant material or bandage material releasing medication preparation RU2176525C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/345,889 US5660854A (en) 1994-11-28 1994-11-28 Drug releasing surgical implant or dressing material
US08/345,889 1994-11-28

Publications (2)

Publication Number Publication Date
RU97112474A true RU97112474A (en) 1999-05-27
RU2176525C2 RU2176525C2 (en) 2001-12-10

Family

ID=23356955

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97112474/14A RU2176525C2 (en) 1994-11-28 1995-11-28 Surgical implant material or bandage material releasing medication preparation

Country Status (14)

Country Link
US (2) US5660854A (en)
EP (1) EP0790823B1 (en)
JP (1) JPH10511019A (en)
KR (1) KR100382987B1 (en)
AT (1) ATE244561T1 (en)
AU (1) AU698113B2 (en)
CA (1) CA2206259A1 (en)
DE (1) DE69531254T2 (en)
DK (1) DK0790823T3 (en)
ES (1) ES2202382T3 (en)
MX (1) MX9703912A (en)
PT (1) PT790823E (en)
RU (1) RU2176525C2 (en)
WO (1) WO1996016643A1 (en)

Families Citing this family (423)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114594A (en) * 1992-01-24 2000-09-05 Societe Precis Method of treating a wound using dressing product with core of alginate fibers
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
BR9508723A (en) 1994-08-17 1998-01-06 Eth Zuerich Implant implantation method and application device
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
DE69812941T2 (en) * 1997-01-30 2004-02-05 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE DEFENSE
US6713527B2 (en) * 1997-02-07 2004-03-30 Queen's University At Kingston Anaesthetic bone cement
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US6589199B1 (en) 1997-08-28 2003-07-08 Boston Scientific Corporation System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber
AU8913998A (en) 1997-08-28 1999-03-22 Boston Scientific Corporation System for implanting a cross-linked polysaccharide fiber and methods of formingand inserting the fiber
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
US5928174A (en) * 1997-11-14 1999-07-27 Acrymed Wound dressing device
JP2006111636A (en) * 1997-12-26 2006-04-27 Astellas Pharma Inc Sustained release pharmaceutical composition
EP1079808B1 (en) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
DE19825499C2 (en) * 1998-06-08 2003-07-17 Beiersdorf Ag Patches containing active ingredients
SE514908C2 (en) * 1998-07-13 2001-05-14 Gs Dev Ab Means for bone reconstruction
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
NZ511792A (en) 1998-11-20 2003-08-29 Skyepharma Canada Inc Dispersible phospholipid stabilized microparticles
DE19856668A1 (en) * 1998-12-09 2000-06-15 Aesculap Ag & Co Kg Active substance matrix in the form of a bioabsorbable porous nonwoven, process for its preparation and use
US6454787B1 (en) 1998-12-11 2002-09-24 C. R. Bard, Inc. Collagen hemostatic foam
US6361551B1 (en) * 1998-12-11 2002-03-26 C. R. Bard, Inc. Collagen hemostatic fibers
US6143946A (en) * 1998-12-24 2000-11-07 Docter; Joan E. Therapeutic mat
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US20040171323A1 (en) * 1999-02-17 2004-09-02 Shalaby Shalaby W. Antimicrobial, synthetic, fibrous, and tubular medical divices
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US7186260B2 (en) * 1999-04-29 2007-03-06 Hyson Morton I Medicated wrap
DE60031114T2 (en) 1999-06-11 2007-05-03 Cytyc Corp., Marlborough LIQUID GEL FORMULATION FOR DETECTING MILK CHANNELS IN THE CHEST BEFORE SURGICAL ABLATION OF THE BREAST TISSUE
US6398808B1 (en) * 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
US6385491B1 (en) * 1999-10-04 2002-05-07 Medtronic, Inc. Temporary medical electrical lead having biodegradable electrode mounting pad loaded with therapeutic drug
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
GB2357435A (en) * 1999-12-23 2001-06-27 Johnson & Johnson Medical Ltd Absorbent medicinal articles
WO2001049258A2 (en) * 1999-12-30 2001-07-12 Acrymed Methods and compositions for improved delivery devices
US20030095993A1 (en) * 2000-01-28 2003-05-22 Hanne Bentz Gel-infused sponges for tissue repair and augmentation
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (en) 2000-05-10 2004-07-16 Alliance Pharma Phospholipid-based powders for drug delivery.
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6309454B1 (en) * 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US6521244B1 (en) * 2000-06-13 2003-02-18 Nozomu Kanesaka Body filling material
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US8033983B2 (en) 2001-03-09 2011-10-11 Boston Scientific Scimed, Inc. Medical implant
WO2002071931A1 (en) 2001-03-09 2002-09-19 Scimed Life Systems, Inc. Medical slings
US8187625B2 (en) * 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
FR2824470B1 (en) * 2001-05-11 2003-08-29 Brothier Lab ALGINATE FIBER BANDING PRODUCT WITH ENVELOPE
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US20040142013A1 (en) * 2001-07-13 2004-07-22 Flow Focusing, Inc. Implantable orthopedic surgical devices with controlled release antimicrobial component
US20050129732A1 (en) * 2001-07-13 2005-06-16 Flow Focusing, Inc. Biodegradable, antibiotic, controlled release tape
US20070254008A1 (en) * 2001-07-13 2007-11-01 Flow Focusing, Inc. Antibiotic formulation and method of treatment
US20070254009A1 (en) * 2001-07-13 2007-11-01 Flow Focusing, Inc. Antibiotic/bone morphogenic protein formulation and method of treatment
US20060263401A1 (en) * 2001-07-13 2006-11-23 Flow Focusing, Inc. Formulation and Method for Preventing Infection
DE60204158T2 (en) * 2001-10-05 2006-02-02 SurModics, Inc., Eden Prairie COATINGS WITH IMMOBILIZED PARTICLES AND USES THEREOF
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US20030099693A1 (en) * 2001-11-02 2003-05-29 Auffret Anthony David Wafer
IL162001A0 (en) 2001-11-14 2005-11-20 Alza Corp Catheter injectable depot compositions and uses thereof
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US20030153947A1 (en) * 2002-02-14 2003-08-14 Tomoaki Koseki Sternum suture material and its manufacturing method
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP1517684B1 (en) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US7252837B2 (en) 2002-06-28 2007-08-07 Ethicon, Inc. Hemostatic wound dressing and method of making same
US7279177B2 (en) 2002-06-28 2007-10-09 Ethicon, Inc. Hemostatic wound dressings and methods of making same
US8486426B2 (en) * 2002-07-29 2013-07-16 Kimberly-Clark Worldwide, Inc. Methods and compositions for treatment of dermal conditions
KR20050038008A (en) 2002-07-31 2005-04-25 알자 코포레이션 Injectable depot compositions and uses thereof
EP2030611A1 (en) 2002-07-31 2009-03-04 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
EP1572115B1 (en) 2002-11-27 2015-01-21 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
CA2509914A1 (en) * 2002-12-11 2004-06-24 Ferrosan A/S Gelatine-based materials as swabs
AU2003259834A1 (en) 2002-12-17 2004-07-29 Boston Scientific Limited Spacer for sling delivery system
US20040185009A1 (en) * 2003-03-19 2004-09-23 Dexcel Pharma Technologies Ltd. Composition and device for treating periodontal diseases
US7019191B2 (en) * 2003-03-25 2006-03-28 Ethicon, Inc. Hemostatic wound dressings and methods of making same
DE10315640A1 (en) * 2003-04-04 2004-10-14 Ignatov, Konstantin Process for the controlled release of components into a solution
WO2004099158A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
US20040248877A1 (en) * 2003-04-30 2004-12-09 Sandeep Gupta Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof
JP4847868B2 (en) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド Compounds and their use in the regulation of amyloid beta
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20040243044A1 (en) * 2003-06-02 2004-12-02 Penegor Stephen A. Hemostatic wound dressing
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7361138B2 (en) 2003-07-31 2008-04-22 Scimed Life Systems, Inc. Bioabsorbable casing for surgical sling assembly
US20050036955A1 (en) * 2003-08-13 2005-02-17 Degould Michael D. Bioresorbable tooth extraction socket dressing
KR20060088543A (en) * 2003-09-25 2006-08-04 디엠아이 바이오사이언스 인코포레이티드 Methods and products which utilize n-acyl-l-aspartic acid
US9579294B1 (en) * 2004-01-02 2017-02-28 New Medical Technology, Inc Scar tissue dressing
US20080131493A1 (en) * 2004-01-02 2008-06-05 Haitham Matloub Method and Multilayered Device for Controlled Topical Delivery of Therapeutic Agents to the Skin
JP2007519450A (en) * 2004-01-30 2007-07-19 フェロサン アー／エス Hemostasis sprays and compositions
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8467875B2 (en) 2004-02-12 2013-06-18 Medtronic, Inc. Stimulation of dorsal genital nerves to treat urologic dysfunctions
US20090216252A1 (en) * 2004-02-13 2009-08-27 The University Of Cincinnati A coupling device enabled by mechanical continuity of cellular scaffolding across tissue boundaries
CN100558415C (en) * 2004-02-28 2009-11-11 汉莫堤克科技公司 The biocompatible coating of medical surfaces, method and purposes
WO2005113523A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2005120578A2 (en) * 2004-06-07 2005-12-22 California Institute Of Technology Biodegradable drug-polymer delivery system
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20060002970A1 (en) * 2004-07-01 2006-01-05 Aspenberg Per V Method for coating a suture
EP1786421A2 (en) * 2004-07-09 2007-05-23 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
CN101001649B (en) * 2004-07-09 2011-08-31 弗罗桑医疗设备公司 Haemostatic composition comprising hyaluronic acid and its preparation method
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
CN102783499A (en) * 2004-07-30 2012-11-21 金伯利-克拉克环球有限公司 Antimicrobial devices and compositions
AU2005280443B2 (en) * 2004-07-30 2011-02-03 Avent, Inc. Antimicrobial silver compositions
EP1841749A1 (en) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
AU2005287137B2 (en) 2004-09-17 2012-03-22 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods of inhibiting a-synuclein toxicity
US9289378B2 (en) 2004-09-20 2016-03-22 Avent, Inc. Antimicrobial amorphous compositions
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US20060078589A1 (en) * 2004-10-12 2006-04-13 Jensen Steven D Device for treating oral wound gaps
US9358318B2 (en) 2004-10-20 2016-06-07 Ethicon, Inc. Method of making a reinforced absorbable multilayered hemostatic wound dressing
EP2345430B1 (en) 2004-10-20 2015-11-25 Ethicon, Inc. A reinforced absorbable multilayered fabric for use in medical devices and method of manufacture
WO2006044882A2 (en) * 2004-10-20 2006-04-27 Ethicon, Inc. A reinforced absorbable multilayered hemostatic wound dressing and method of making
FR2877846B1 (en) * 2004-11-15 2008-12-05 Univ Lille Sciences Tech BIOMATERIAL CARRIERS OF CYCLODEXTRINS WITH IMPROVED ABSORPTION PROPERTIES AND PROGRESSIVE AND DELAYED RELEASE OF THERAPEUTIC MOLECULES
AU2005314426A1 (en) 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20070005213A1 (en) * 2005-06-30 2007-01-04 Hyundai Autonet Co., Ltd. Backward control for automobiles using telematics and method thereof
CN101287507B (en) * 2005-08-12 2012-12-05 刘江 Methods and devices for lymphatic targeting
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US20070110786A1 (en) * 2005-11-15 2007-05-17 Boston Scientific Scimed, Inc. Medical articles having enhanced therapeutic agent binding
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US8663674B2 (en) * 2006-01-13 2014-03-04 Surmodics, Inc. Microparticle containing matrices for drug delivery
US8795730B2 (en) * 2006-01-31 2014-08-05 David John Vachon Compositions and methods for promoting the healing of tissue of multicellular organisms
US7809443B2 (en) 2006-01-31 2010-10-05 Medtronic, Inc. Electrical stimulation to alleviate chronic pelvic pain
US20070191816A1 (en) * 2006-02-13 2007-08-16 Boston Scientific Scimed, Inc. Radio frequency induced drug elution
AU2007221050B2 (en) * 2006-02-28 2012-08-30 Covidien Lp Antimicrobial medical devices
CN101443314B (en) * 2006-03-13 2014-04-09 杏林制药株式会社 Aminoquinolones as GSK-3 inhibitors
EA200870385A1 (en) * 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. INHIBITION OF TOXICITY ALPHA-SINUCLEINE
US7761166B2 (en) * 2006-04-28 2010-07-20 Medtronic, Inc. Electrical stimulation of iliohypogastric nerve to alleviate chronic pelvic pain
US20070253997A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Drug delivery to alleviate chronic pelvic pain
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
US20070255324A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Drug delivery to ilioinguinal nerve to alleviate chronic pelvic pain
US20070255333A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Neuromodulation therapy for perineal or dorsal branch of pudendal nerve
US8219202B2 (en) * 2006-04-28 2012-07-10 Medtronic, Inc. Electrical stimulation of ilioinguinal nerve to alleviate chronic pelvic pain
US7638344B2 (en) * 2006-06-28 2009-12-29 Surmodics, Inc. Active agent eluting matrices with particulates
WO2008006083A2 (en) 2006-07-07 2008-01-10 Surmodics, Inc. Beaded wound spacer device
MX2009002151A (en) 2006-08-28 2009-07-03 Kirin Pharma Kk Antagonistic human light-specific human monoclonal antibodies.
JP2010504333A (en) * 2006-09-20 2010-02-12 タイコ ヘルスケア グループ リミテッド パートナーシップ New triclosan salt
PT2066662E (en) 2006-09-21 2013-02-13 Kyorin Seiyaku Kk Serine hydrolase inhibitors
EP2081893B1 (en) 2006-10-19 2011-03-23 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2008077103A1 (en) 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
EP2125739A1 (en) * 2006-12-22 2009-12-02 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
PL2144604T3 (en) * 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Methods for the treatment of chronic viral hepatitis C using RO 113-0830
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
DK2125698T3 (en) 2007-03-15 2016-11-07 Auspex Pharmaceuticals Inc Deuterated d9-VENLAFAXINE
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
CN101801188A (en) * 2007-07-12 2010-08-11 特拉加拉医药品公司 Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
CN101855228B (en) * 2007-09-11 2012-10-24 杏林制药株式会社 Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
EP2203459B1 (en) 2007-09-12 2016-03-16 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as gsk-3 inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
JP2011504485A (en) 2007-11-21 2011-02-10 ファーマクシス リミテッド SSAO / VAP-1 haloallylamine inhibitors and uses thereof
EP2254605A4 (en) * 2008-02-22 2012-06-20 Celonova Biosciences Inc Multi-functional wound dressing matrices and related methods
CN102014973A (en) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 Device for promotion of hemostasis and/or wound healing
CA2972138A1 (en) 2008-03-17 2009-09-24 Ambit Biosciences Corporation Raf kinase modulator compounds and methods of use thereof
US8496954B2 (en) * 2008-04-18 2013-07-30 Surmodics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
US20110091577A1 (en) * 2008-04-25 2011-04-21 Silverman Lance D Drug release coatings on calcuim phosphate and uses thereof
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
KR20170029019A (en) * 2008-07-18 2017-03-14 바이오모드 컨셉츠 인코포레이티드 Articles of manufacture releasing an active ingredient
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (en) * 2008-08-29 2010-03-03 首都医科大学宣武医院 Stem cell delivery of antitumor drugs
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
KR20110124787A (en) 2009-02-27 2011-11-17 암비트 바이오사이언시즈 코포레이션 Jak kinase modulating quinazoline derivatives and methods of use thereof
JP5690286B2 (en) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド Phosphothiophene and phosphothiazole HCV polymerase inhibitors
EP2406266B1 (en) * 2009-03-11 2013-12-25 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
JP2012520314A (en) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン Combination of indazolylaminopyrrolotriazine and taxane for cancer treatment
US20100247600A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Therapeutic drug eluting implant cover and method of making the same
CN102448958B (en) 2009-03-27 2015-10-21 维特Dc公司 Pyrimidyl and 1,3,5-triazines base benzimidazole sulfonamides and its purposes in cancer therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US9078712B2 (en) 2009-04-15 2015-07-14 Warsaw Orthopedic, Inc. Preformed drug-eluting device to be affixed to an anterior spinal plate
US9414864B2 (en) * 2009-04-15 2016-08-16 Warsaw Orthopedic, Inc. Anterior spinal plate with preformed drug-eluting device affixed thereto
NZ620074A (en) 2009-04-22 2015-09-25 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
NZ620092A (en) 2009-04-22 2015-07-31 Axikin Pharmaceuticals Inc Arylsulfonamide ccr3 agtagonists
EP2727908A3 (en) 2009-04-22 2014-08-20 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
US20100274295A1 (en) * 2009-04-24 2010-10-28 Warsaw Orthopedic, Inc. Medical implant configured to deliver a therapeutic substance
US8333791B2 (en) * 2009-04-24 2012-12-18 Warsaw Orthopedic, Inc. Medical implant with tie configured to deliver a therapeutic substance
US10806833B1 (en) * 2009-05-11 2020-10-20 Integra Lifesciences Corporation Adherent resorbable matrix
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2767168C (en) 2009-07-08 2019-04-09 Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN102470127A (en) 2009-08-19 2012-05-23 埃姆比特生物科学公司 Biaryl compounds and methods of use thereof
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
EP2499282B1 (en) 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110129801A1 (en) * 2009-11-27 2011-06-02 Shikha Pramanik Barman Compositions and methods to prevent and treat dry socket post-operatively after tooth extraction surgery
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
RU2554087C2 (en) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-condensed arylene or heteroarylene hepatitis c virus inhibitors
US8710092B2 (en) * 2009-12-23 2014-04-29 Map Pharmaceuticals, Inc. Substituted indolo 4,3 FG quinolines useful for treating migraine
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
DK2542542T3 (en) 2010-03-02 2015-07-20 Axikin Pharmaceuticals Inc ISOTOPIC ENRICHED ARYL SULPHONAMIDE CCR3 ANTAGONISTS
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
TW201134820A (en) 2010-03-17 2011-10-16 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
MX2012013879A (en) 2010-06-01 2013-04-03 Biotheryx Inc Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases.
CN103153309A (en) 2010-06-01 2013-06-12 拜欧赛里克斯公司 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
JP2011251944A (en) * 2010-06-02 2011-12-15 Kansai Medical Univ Analgesic preparation for embedding
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
CA2809022C (en) 2010-08-20 2017-01-03 Dr. Reddy`S Laboratories, Inc. Phospholipid depot
US20130225578A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
AU2011296046B2 (en) 2010-09-01 2015-05-14 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030894A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
ES2581840T3 (en) 2010-09-01 2016-09-07 Ambit Biosciences Corporation Optically active pyrazylaminoquinazoline and pharmaceutical compositions and methods of use thereof
EP2663553B1 (en) 2010-09-01 2015-08-26 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
EP2611502A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
JP2013543512A (en) 2010-10-11 2013-12-05 アクシキン ファーマシューティカルズ インコーポレーテッド Arylsulfonamide CCR3 antagonist salts
BR112013009743A2 (en) 2010-10-22 2016-07-19 Reddys Lab Inc Dr use of storage stable viscous phospholipid deposit to treat injuries
US8865198B2 (en) 2010-10-25 2014-10-21 Dexcel Pharma Technologies Ltd. Method for treating a periodontal disease
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
AR085352A1 (en) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS
EP2691389A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012149287A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Solvent cast film sustained release latanoprost implant
BR112013033339A2 (en) 2011-06-23 2016-08-16 Map Pharmaceuticals Inc fluorergoline analogs
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US9381112B1 (en) 2011-10-06 2016-07-05 William Eric Sponsell Bleb drainage device, ophthalmological product and methods
TWI650321B (en) 2011-10-14 2019-02-11 美商安比特生物科學公司 Heterocyclic compound and method of use thereof
WO2013095707A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US8632489B1 (en) 2011-12-22 2014-01-21 A. Mateen Ahmed Implantable medical assembly and methods
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
CA2865349C (en) 2012-03-06 2021-07-06 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
EP2852586A1 (en) 2012-03-16 2015-04-01 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanoparticles for treatment of allergy
AU2013255103B2 (en) 2012-05-02 2016-09-29 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
IN2014MN02214A (en) 2012-05-10 2015-07-17 Painreform Ltd
EP2825216B1 (en) 2012-06-12 2015-08-19 Ferrosan Medical Devices A/S Dry haemostatic composition
EP2861562B1 (en) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2014039748A1 (en) 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
JP6298468B2 (en) 2012-10-16 2018-03-20 サーモディクス，インコーポレイテッド Wound filling device and method
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
CA2892227C (en) 2012-11-30 2020-12-15 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP2934143A4 (en) 2012-12-21 2016-06-15 Map Pharmaceuticals Inc Novel methysergide derivatives
WO2014110305A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
CN105377355A (en) 2013-03-14 2016-03-02 拇趾公司 Method of treating infections, diseases or disorders of nail unit
US9775853B2 (en) * 2013-03-15 2017-10-03 Biomet Manufacturing, Llc. Hemostatic compositions and methods
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
US11173227B2 (en) 2013-05-22 2021-11-16 The Penn State Research Foundation Wound dressings and applications thereof
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
CN105358071B (en) 2013-06-21 2018-07-31 弗罗桑医疗设备公司 The dry composition of vacuum expansion and syringe for retaining the dry composition
KR20160055170A (en) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN105828844B (en) 2013-12-11 2019-09-27 弗罗桑医疗设备公司 Dry composition comprising squeezing out reinforcing agent
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
MX2016012097A (en) 2014-03-20 2017-04-27 Capella Therapeutics Inc Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
EP3444011A1 (en) 2014-05-12 2019-02-20 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with emricasan
PL3148579T3 (en) 2014-05-28 2021-07-19 Agenus Inc. Anti-gitr antibodies and methods of use thereof
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
RU2568919C1 (en) * 2014-07-03 2015-11-20 Павел Васильевич Попрядухин Method of producing biocompatible biodegradable porous composite material
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US10201457B2 (en) 2014-08-01 2019-02-12 Surmodics, Inc. Wound packing device with nanotextured surface
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
US20170319548A1 (en) 2014-09-12 2017-11-09 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CN106999621B (en) 2014-10-13 2020-07-03 弗罗桑医疗设备公司 Dry composition for hemostasis and wound healing
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
ES2834739T3 (en) 2014-12-11 2021-06-18 Pf Medicament Anti-C10orf54 antibodies and their uses
EP3237450B1 (en) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
AU2015371184B2 (en) 2014-12-24 2020-06-25 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
CN107428745A (en) 2015-01-20 2017-12-01 Xoc制药股份有限公司 Ergoline compound and application thereof
EP3247357A4 (en) 2015-01-20 2018-07-11 Xoc Pharmaceuticals, Inc Isoergoline compounds and uses thereof
CN107428749B (en) 2015-01-28 2020-07-24 上海复旦张江生物医药股份有限公司 Substituted imidazo [1,2- α ] pyridin-2-ylamine compounds, pharmaceutical compositions and methods of use thereof
PL3265123T3 (en) 2015-03-03 2023-03-13 Kymab Limited Antibodies, uses & methods
CN113603784A (en) 2015-05-29 2021-11-05 艾吉纳斯公司 anti-CTLA-4 antibodies and methods of use thereof
US20190015396A1 (en) 2015-06-23 2019-01-17 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
BR112017027695A2 (en) 2015-07-03 2018-09-04 Ferrosan Medical Devices As first and second substance retention and mixing syringe
US20180200185A1 (en) 2015-07-23 2018-07-19 Novaflux, Inc Implants and constructs including hollow fibers
MX2018002315A (en) 2015-09-01 2018-04-11 Agenus Inc Anti-pd-1 antibodies and methods of use thereof.
PT3368534T (en) 2015-10-30 2021-03-09 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
PT3394057T (en) 2015-12-23 2022-04-21 Neurocrine Biosciences Inc Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]lsoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
SG11201805480TA (en) 2015-12-31 2018-07-30 Conatus Pharmaceuticals Inc Methods of using caspase inhibitors in treatment of liver disease
US10189808B2 (en) 2016-01-08 2019-01-29 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3808346B1 (en) 2016-01-08 2023-07-19 Celgene Corporation Antiproliferative compounds for use in the treatment of leukemia
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
EP3426352A4 (en) 2016-03-08 2019-11-13 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
JP2019510085A (en) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Nanoparticles and methods and compounds for cancer treatment
AU2017250086A1 (en) 2016-04-11 2018-09-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190160052A1 (en) 2016-05-13 2019-05-30 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI753910B (en) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
JP7267012B2 (en) 2016-05-27 2023-05-01 アジェナス インコーポレイテッド Anti-TIM-3 antibody and method of use thereof
JP2019525772A (en) 2016-07-08 2019-09-12 スターテン・バイオテクノロジー・ベー・フェー Anti-APOC3 antibody and method of use thereof
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
AU2017326558B2 (en) 2016-09-19 2022-01-06 Mei Pharma, Inc. Combination therapy
MX2019003683A (en) 2016-10-11 2019-08-22 Agenus Inc Anti-lag-3 antibodies and methods of use thereof.
DK3528856T3 (en) 2016-10-18 2023-10-16 Univ Marquette Composite materials containing structural polymers and photoreactive nitrogen oxide releasing agents and uses thereof for wound dressings
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7045724B2 (en) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド Anti-Family 19, member A5 antibody with sequence similarity and its uses
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CA3042055A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. Methods for the treatment of cancer
US20200078352A1 (en) 2016-12-02 2020-03-12 Neurocrine Biosciences, Inc. Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
JP7106538B2 (en) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド Antibodies and methods of their use
MD3551660T2 (en) 2016-12-07 2024-03-31 Agenus Inc Anti-CTLA-4 antibodies and methods of use thereof
SG11201906883SA (en) 2017-01-27 2019-08-27 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
AU2018220515B2 (en) 2017-02-17 2022-06-30 DayLife LLC Universal antivenom
SG11201906922TA (en) 2017-02-17 2019-09-27 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
MX2019011624A (en) 2017-03-27 2019-12-05 Celgene Corp Methods and compositions for reduction of immunogenicity.
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
SI3618863T1 (en) 2017-05-01 2023-12-29 Agenus Inc. Anti-tigit antibodies and methods of use thereof
JOP20190219A1 (en) 2017-05-09 2019-09-22 Cardix Therapeutics LLC Pharmaceutical compositions and methods of treating cardiovascular diseases
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
BR112019025420A2 (en) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. POLYCYCLICAL COMPOUNDS AND USES OF THESE
KR102472683B1 (en) 2017-06-27 2022-12-01 주식회사 뉴라클사이언스 Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of glaucoma
US11560425B2 (en) 2017-06-27 2023-01-24 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
EP3645563A4 (en) 2017-06-27 2021-03-17 Neuracle Science Co., Ltd Anti-fam19a5 antibodies and uses thereof
JP7034499B2 (en) 2017-06-27 2022-03-14 ニューラクル サイエンス カンパニー リミテッド Uses of anti-FAM19A5 antibody for the treatment of fibrosis
EP4265257A1 (en) 2017-09-01 2023-10-25 East Carolina University Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer
WO2019060322A2 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
WO2019071021A2 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California Immunomodulatory oligosaccharides
CN116492340A (en) 2017-10-10 2023-07-28 纽罗克里生物科学有限公司 Methods of administering certain VMAT2 inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
PE20210119A1 (en) 2017-10-31 2021-01-19 Staten Biotechnology B V ANTI-APOC3 ANTIBODIES AND METHODS OF USE OF THEM
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
CA3094711A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
CN112424223A (en) 2018-04-24 2021-02-26 纽洛可科学有限公司 Use of an antibody against member a5 of sequence similarity family 19 for the treatment of neuropathic pain
ES2968412T3 (en) 2018-05-09 2024-05-09 Ferrosan Medical Devices As Method for preparing a hemostatic composition
KR102661891B1 (en) 2018-05-10 2024-05-23 주식회사 뉴라클사이언스 Anti-family with sequence similarity 19, member A5 antibody and methods of use thereof
BR112020024018A2 (en) 2018-06-14 2021-02-23 Neurocrine Biosciences Inc. vmat2 inhibitor compounds, compositions and methods related to them
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
MX2021000786A (en) 2018-07-20 2021-06-15 Pf Medicament Receptor for vista.
KR20210044817A (en) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 Methods of Administration of Specific VMAT2 Inhibitors
TWI834708B (en) 2018-08-17 2024-03-11 美商文涵治療有限公司 Formulations of ag10
AU2019328276A1 (en) * 2018-08-31 2021-03-18 Rilento Pharma, Llc Pharmaceutical formulation and system and method for delivery
CA3113575A1 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
WO2020080496A1 (en) * 2018-10-17 2020-04-23 東レ株式会社 Hemostatic material
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
KR20200071198A (en) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Development of new adoptive T cell immunotherapy by modification of Nrf2 expression
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020163554A1 (en) 2019-02-06 2020-08-13 Dice Alpha, Inc. Il-17a modulators and uses thereof
MA55080A (en) 2019-02-26 2022-01-05 Inspirna Inc HIGH AFFINITY ANTI-MERTK ANTIBODIES AND ASSOCIATED USES
US11597703B2 (en) 2019-03-07 2023-03-07 Histogen, Inc. Caspase inhibitors and methods of use thereof
CN114222803A (en) 2019-05-20 2022-03-22 尼尔瓦纳科学股份有限公司 Narrow emission dyes, compositions comprising the same, and methods of making and using the same
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
AU2020311404A1 (en) 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
TW202122420A (en) 2019-08-30 2021-06-16 美商艾吉納斯公司 Anti-cd96 antibodies and methods of use thereof
BR112022004802A2 (en) 2019-09-16 2022-08-23 Dice Alpha Inc IL-17A MODULATORS AND USES THEREOF
JPWO2021112254A1 (en) * 2019-12-06 2021-06-10
JP2023512456A (en) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Methods of treating tumors with a combination of IL-7 protein and bispecific antibody
KR20220140711A (en) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods
EP4093751A1 (en) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimeric polypeptides
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US11529331B2 (en) 2020-05-29 2022-12-20 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (en) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4236989A1 (en) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Use of interleukin-7 for the treatment of coronavirus
EP4240408A1 (en) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
JP2024500377A (en) 2020-12-14 2024-01-09 バイオセリックス， インコーポレイテッド PDE4 degraders, pharmaceutical compositions, and therapeutic applications
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022256437A1 (en) 2021-06-02 2022-12-08 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
WO2022266248A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2023055045A1 (en) 2021-09-29 2023-04-06 주식회사 엔바이오스 Coiled-coil fusion protein
US12017997B2 (en) 2021-10-22 2024-06-25 Prosetta Biosciences, Inc. Host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
TW202342070A (en) 2022-03-30 2023-11-01 美商拜奧馬林製藥公司 Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US20230331693A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the novel compounds
US20230416741A1 (en) 2022-05-05 2023-12-28 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
WO2023220640A1 (en) 2022-05-10 2023-11-16 Biotheryx, Inc. Cdk protein degraders, pharmaceutical compositions, and therapeutic applications
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
US20240131005A1 (en) 2022-09-30 2024-04-25 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
US20240209100A1 (en) 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2430740A (en) * 1942-08-29 1947-11-11 Arthur E Sharples Therapeutic dressing
US2804424A (en) * 1951-04-24 1957-08-27 American Cyanamid Co Method of preparing a tetracycline type antibiotic-containing wound dressing
US2809149A (en) * 1954-12-23 1957-10-08 Cusumano Frank Ramo Antibiotic-impregnated gauze pads and method of making same
US2830011A (en) * 1957-02-07 1958-04-08 American Cyanamid Co Textile fabrics containing neomycin
US3642003A (en) * 1969-08-26 1972-02-15 Sutures Inc Sutures having long-lasting germicidal properties
US3987797A (en) * 1974-02-25 1976-10-26 Ethicon, Inc. Antimicrobial sutures
US4027676A (en) * 1975-01-07 1977-06-07 Ethicon, Inc. Coated sutures
US4024871A (en) * 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
DE2650306A1 (en) * 1976-11-02 1978-05-03 Merck Patent Gmbh ANTIBACTERIAL DRESSING AND METHOD OF ITS MANUFACTURING
JPS5434493A (en) * 1977-08-17 1979-03-13 Tatsuo Fukuoka Fiber
US4265233A (en) * 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
US4373519A (en) * 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
DE3212735A1 (en) * 1982-04-06 1983-10-06 Bayer Ag Membrane for active-substance liberation and active-substance resorption models
US5197977A (en) * 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
MX163953B (en) * 1984-03-27 1992-07-03 Univ New Jersey Med PROCEDURE FOR PREPARING A BIODEGRADABLE COLLAGEN MATRIX
US4837285A (en) * 1984-03-27 1989-06-06 Medimatrix Collagen matrix beads for soft tissue repair
US4847049A (en) * 1985-12-18 1989-07-11 Vitaphore Corporation Method of forming chelated collagen having bactericidal properties
US4643181A (en) * 1986-04-04 1987-02-17 Surgikos, Inc. Antimicrobial dressing or drape material
US5061689A (en) * 1986-12-24 1991-10-29 Bioderm, Inc. Zinc bacitracin containing wound dressing
US5064653A (en) * 1988-03-29 1991-11-12 Ferris Mfg. Co. Hydrophilic foam compositions
US5006071A (en) * 1988-05-09 1991-04-09 Carter Dewey G Technique for the prevention of alveolar osteitis
CA1340241C (en) * 1988-06-08 1998-12-15 Fountain Pharmaceuticals, Inc. Method for marking solvent dilution microcarriers
US5133965A (en) * 1988-06-08 1992-07-28 Fountain Pharmaceuticals, Inc. Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution
US5124155A (en) * 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
US5116620A (en) * 1989-11-21 1992-05-26 Bruce A. Barber Antimicrobial wound dressing
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5196190A (en) * 1990-10-03 1993-03-23 Zenith Technology Corporation, Limited Synthetic skin substitutes
ATE224808T1 (en) * 1992-08-17 2002-10-15 Weyerhaeuser Co METHOD FOR BONDING PARTICLES TO FIBERS

Similar Documents

Publication Publication Date Title
RU97112474A (en) MEDICINAL EMISSION SURGICAL IMPLANT OR BANDBANDING MATERIAL
EP0790823B1 (en) Drug releasing surgical implant or dressing material
US20210093566A1 (en) Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same
ES2730410T3 (en) Material for the treatment of advanced heart failure as a myocardial / cardiovascular regeneration device
JP4545315B2 (en) Material for delivering active compound and drug delivery device comprising same
US20040151774A1 (en) Therapeutic compositions for drug delivery to and through covering epithelia
CA2493604C (en) Patch containing fentanyl for mucous membrane of oral cavity
JPH10502673A (en) Formulations and methods for providing sustained local anesthesia
AU5429790A (en) The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
EP0160266A2 (en) Liposome composition
CZ2015477A3 (en) Pharmaceutical composition
JP2001519787A (en) Intravesical drug delivery system
US20070196500A1 (en) Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
Shabbir et al. Lipid vesicles and nanoparticles for non-invasive topical and transdermal drug delivery
JP2007510628A (en) Promotion of transdermal administration of hydrophilic drugs
JPH07106978B2 (en) Complex patch preparation
JP6449166B2 (en) Drug-eluting stent graft
JPWO2019044916A1 (en) Drug-supported thin film
MXPA00009675A (en) Liposome composition and method for administering a quinolone